SR

Shantilal Rajmal Jain

Active Director Director DIN 00457742
DIN 00457742 First appointment Apr 2004 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 3 historical roles
Total affiliations 6 Since Apr 2004
Shareholding value •••• Premium profile

About Shantilal Rajmal Jain

Data last updated:

Shantilal Rajmal Jain is a Director at Ripharma Laboratories Limited (since 2025), Director at Skyline Construtech Private Limited (since 2025) and Director at Raja-Nava Developers Pvt Ltd (since 2025). The companies operate in Pharma, Real Estate and Construction and Home & Lifestyle. The 2 current companies with reported revenue have a combined latest revenue of ₹68.32 Cr; the largest is Ripharma Laboratories Limited at ₹68.14 Cr (FY 2025). Earlier, Shantilal Rajmal Jain was a Director at Rishabh Indotex Limited (2004–2018) and Director at Liberal Tradeplace Private Limited (from 2007) and 1 more.

DIN 00457742
Primary Designation Director
Industry Pharma
First Appointment 24 Apr 2004
Oldest Company Age 34 yrs
Largest company Ripharma Laboratories Limited · ₹68.14 Cr (FY 2025)
Combined revenue ₹68.32 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ripharma Laboratories Limited U24100MH2015PLC262970
Director04 Feb 20252015₹68.14 Cr (FY 2025)Active
Skyline Construtech Private Limited U45400MH2012PTC236665
Director15 Jul 20252012₹18.8 Lakh (FY 2025)Active
Raja-Nava Developers Pvt Ltd U45200MH1992PTC066674
Director04 Feb 20251992Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Rishabh Indotex Limited U17120MH2004PLC145794
Director24 Apr 20042004₹1,765 (FY 2024)Active
Liberal Tradeplace Private Limited U51909MH2005PTC153296
Director15 Dec 20072005Strike Off
Partner14 Jul 20142014Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Liberal Tradeplace Private Limited
Ripharma Laboratories Limited
Skrk Properties Llp
Skyline Construtech Private Limited
Premium access

Shareholding and investment profile for Shantilal Rajmal Jain

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shantilal Rajmal Jain

Shantilal Rajmal Jain currently holds 3 directorships: Ripharma Laboratories Limited (Director, since 04 Feb 2025, revenue ₹68.14 Cr (FY 2025)); Skyline Construtech Private Limited (Director, since 15 Jul 2025, revenue ₹18.8 Lakh (FY 2025)); Raja-Nava Developers Pvt Ltd (Director, since 04 Feb 2025).

Shantilal Rajmal Jain was first appointed on 24 Apr 2004 as Director at Rishabh Indotex Limited. The most recent appointment on record is 15 Jul 2025 at Skyline Construtech Private Limited.

The 2 current companies of Shantilal Rajmal Jain that report revenue have a combined latest revenue of ₹68.32 Cr: Ripharma Laboratories Limited ₹68.14 Cr (FY 2025); Skyline Construtech Private Limited ₹18.8 Lakh (FY 2025).

Shantilal Rajmal Jain held 3 earlier board appointments: Rishabh Indotex Limited (Director, 24 Apr 2004 to 16 Sep 2018); Liberal Tradeplace Private Limited (Director, from 15 Dec 2007); Skrk Properties Llp (Partner, from 14 Jul 2014).

The current boards of Shantilal Rajmal Jain's companies include Amit Shantilal Jain (Ripharma Laboratories Limited), Milan Champalal Jain (Ripharma Laboratories Limited), Rishabh Shreepal Jain (Ripharma Laboratories Limited), Shreepal Champalal Jain (Ripharma Laboratories Limited), Shrenik Champalal Jain (Ripharma Laboratories Limited), Bharat Kishormal Shah (Raja-Nava Developers Pvt Ltd), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available